
Eagle's Eye View: Your Weekly CV Update From ACC.org
American College of CardiologyAudio
- Format:
- Podcast
- New episodes:
- Weekly
- Typical length:
- about 9 minutes
- Latest episode:
About this show
The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
Covers: cardiology, cardiovascular health, clinical trials, hypertension, atrial fibrillation, heart failure, coronary artery disease, clinical guidelines
Show details and episodes come from the publisher's public feed at rss.libsyn.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
Eagle's Eye View is a weekly cardiovascular podcast from the American College of Cardiology, covering guidelines, research and quality tools. Recent episodes cover AHA and TCT conference studies, underdiagnosed atrial fibrillation in Black adults, firefighter cardiac deaths and exercise prescription.
Cosmos
Similar in subject
- This Week in Cardiology
Both cover: atrial fibrillation, heart failure, clinical trials - Circulation on the Run
Both cover: heart failure, cardiovascular health, cardiology - JAMA Medical News
Both cover: hypertension, cardiology
Similar shows
Explore more
Episodes
Lifestyle Intervention, Metformin and Multimorbidity Risk in Prediabetes; Hypertension, Hyperlipidemia and Chronic Kidney Disease, Resistance Training & Myocardial Infarction
· 9 min
In this week's View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training, particularly when combined with aerobic exercise, is associated with a lower risk of cardiovascular (CV) disease, especially myocardial infarction, in women. Finally, he discusses the CAMERA-MRI II study in patients with atrial fibrillation and left ventricular systolic dysfunction (LVSD), where catheter ablation significantly improved left ventricular ejection fraction (LVEF) regardless of late gadolinium enhancement status. Subscribe to Eagle's Eye View
Not rated yetRace and Sex Disparities in Mitral Valve Edge-to-Edge Repair
· 8 min
In this week's View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure reduction with spironolactone/dapagliflozin compared to dapagliflozin alone. Next, he discusses the FAVOR III trial, which found that QFR-guided percutaneous coronary intervention improved five-year outcomes versus angiography guidance, with most benefits occurring in the first two years. Lastly, Dr. Eagle examines two renal disease studies addressing optimal chronic kidney disease (CKD) GFR thresholds and the benefits of finerenone in CKD patients.
Not rated yetImpact of Semaglutide And Survival Outcomes In Patients With T2D and CKD
· 7 min
In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally, Dr. Eagle discusses recent findings on antihypertensive drug combinations, emphasizing those regimens that provide optimal efficacy while minimizing adverse effects that often lead to early treatment discontinuation.
Not rated yetPostpartum Cardiovascular Care; 'Low Risk' Chest Pain in the ER; Heart Failure Risk Detection & CV Outcomes with Implantable Devices
· 9 min
In this week's View, Dr. Eagle looks at recent research found in ACC's new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining 'low risk' chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appendage occlusion (LAAO) device implantation. Finally, Dr. Eagle summarizes the ALLEVIATE-HF trial that explored heart failure (HF) risk detection with an insertable cardiac monitor paired with a centrally coordinated nurse-led diuretic intervention. Subscribe to Eagle's Eye View
Not rated yetMaintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan & HFpEF & Functional MR; Digitoxin & Heart Failure
· 9 min
In this week's View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new study on the use of digitoxin and digoxin in patients with heart failure. Subscribe to Eagle's Eye View
Not rated yetHCM, NT-proBNP and HCM Risk Evaluation; Arrhythmic Burden in Cardiac Amyloidosis Obesity and Heart Failure; Postural Orthostatic Tachycardia Syndrome (POTS)
· 8 min
In this week's View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, highlighting key findings and clinical implications. Finally, he summarizes new evidence on the use of ivabradine and propranolol in treating postural orthostatic tachycardia syndrome (POTS). Subscribe to Eagle's Eye View
Not rated yetRhythm Control & Tricuspid Valve Regurgitation; Benefits of Blood Pressure Control on Cardiovascular Disease; Switching DOAC Therapy in AFIB Patients with Stroke; Pulsed Field Ablation & Persistent AFib
· 9 min
In this week's View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. He then explores evidence showing that blood pressure reduction can deliver comparable cardiovascular benefits for patients with chronic kidney disease (CKD). Another study reviewed in this episode assesses the outcomes of continuing versus switching direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation (AFib) who experience breakthrough stroke. Finally, Dr. Eagle summarizes the AVANTE-GUARD trial, which evaluates pulsed field ablation as a first-line treatment for patients with persistent AFib. Subscribe to Eagle's Eye View
Not rated yetPulsed Field Ablation and PAS; TRIDENT & Antihypertensive Polypharmacy; NOBLE and PCI vs. CABG
· 8 min
In this week's View, Dr. Eagle looks at the NOBLE trial evaluating whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is best for patients with unprotected left main coronary artery disease (CAD). He then explores a report highlighting nanosecond pulsed field ablation (nsPFA) and its safety and efficacy at one year for paroxysmal atrial fibrillation. Finally, Dr. Eagle presents a summary of the TRIDENT trial, which compares a triple‑pill antihypertensive strategy with conventional therapy and finds a positive impact on hypertension management and stroke risk following intracerebral hemorrhage. Subscribe to Eagle's Eye View
Not rated yetBenefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans
· 9 min
In this week's View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. He then explores current evidence and strategies to address sex hormone-associated thrombotic and cardiovascular risk. Next, Dr. Eagle examines the OCEANIC-STROKE trial which studied asundexian and its potential to lower recurrent stroke risk in patients with noncardioembolic stroke or transient ischemic attack. Finally, Dr. Eagle asks the question, is high cardiorespiratory fitness associated with longer lifespan and lower multimorbidity? Subscribe to Eagle's Eye View
Not rated yetEarly Surgery for AS; Blood Pressure Trajectories; PCI vs Medical Therapy for Chronic Coronary Disease
· 7 min
In this week's View, Dr. Eagle examines early surgery for asymptomatic patients with severe aortic stenosis. He then reviews evidence linking blood pressure trajectories and rapid control to significantly improved outcomes. Finally, he compares percutaneous coronary intervention with medical therapy for chronic total occlusion in patients with chronic coronary disease. Subscribe to Eagle's Eye View
Not rated yetCaring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans
· 9 min
In this week's View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework for cardiogenic shock survivorship. He then analyzes the new Joint Clinical Statement focusing on Masters athletes with abnormal cardiovascular findings, followed by details on a study of how participation in the BALANCE Model will impact Medicare spending on semaglutide. Finally, Dr. Eagle discusses how modifiable barriers may improve access to quadruple guideline-directed medical therapy for veterans with heart failure with reduced ejection fraction. Subscribe to Eagle's Eye View
Not rated yetTop Takeaways from ACC.26
· 11 min
In this week's View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30. Important studies discussed include: - CHAMPION-AF: Left atrial appendage closure vs. anticoagulation for AFib - VESALIUS-CV: Evolocumab reduces CV risk in diabetic patients without ASCVD - Ez-PAVE: Hitting lower LDL-C target reduces major CV events - PRO-TAVI: Should high-risk patients undergo PCI before TAVI? - SMART-DECISION: Discontinuing beta-blockers safe 1 year post MI For stable patients - GoFreshRx: How home-delivered DASH groceries improve blood pressure (BP) and LDL-C - THRIVE: Exploring the positive effects of a culturally tailored "food-is medicine" program on lowering BP
Not rated yetNew ACC/AHA Dyslipidemia Guidelines Released
· 8 min
In this week's View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA's newly released clinical guidelines for managing dyslipidemia. Subscribe to Eagle's Eye View
Not rated yetBeta-Blocker vs. Calcium-Channel Blocker in HCM
· 9 min
In this week's View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion (LAAO). Finally, the iModern trial, which compares immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease, is discussed. Subscribe to Eagle's Eye View
Not rated yetIncreased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation
· 7 min
In this week's View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). He then explores the PREDIMED trial which found that adherence to the Mediterranean diet plus moderate wine intake was associated with reduced cardiovascular risk and mortality. Finally, Dr. Eagle examines 20-year outcomes for pulmonary vein isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (AFib). Subscribe to Eagle's Eye View
Not rated yetSelf-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism
· 7 min
In this week's View, Dr. Eagle looks at findings from the Evolut Low Risk trial (https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063) in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release of the AHA/ACC guideline for treatment and management of acute pulmonary embolism (PE) in adults. Subscribe to Eagle's Eye View
Not rated yetORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF
· 8 min
In this week's View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels in treating patients who have either heart failure (HF) or HF with preserved ejection fraction (HFpEF). Subscribe to Eagle's Eye View
Not rated yetExercise Testing & Systolic Blood Pressure; the Navitor TAVR valve; the ABILITY Diabetes Global Trial & Stent Comparisons for People with Diabetes
· 7 min
In this week's View, Dr. Eagle looks at exercise systolic blood pressure (SBP) during stress testing related to cardiovascular (CV) events. He then explores the novel Navitor transcatheter heart valve (THV) and its safety and effectiveness in younger patients requiring transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle examines the value of 18F-FAPI PET/CT imaging and its role in assessing risk in patients with pulmonary arterial hypertension (PAH). Subscribe to Eagle's Eye View
Not rated yetThe State of CV Health in the US; Semaglutide and Reduced Hospital Admissions; D-Dimer and Its Use in Ruling Out DVT
· 7 min
In this week's View, Dr. Eagle comments on the recently published JACC Cardiovascular (CV) Statistics report which evaluates the management of CV risk factors in the United States. He then explores the use of semaglutide and its association with reduced hospital admissions and length of stay. Finally, Dr. Eagle examines the multicenter, multinational ADJUST-DVT study on the age-adjusted use of D-dimer cut-offs for patients with suspected deep vein thrombosis. Subscribe to Eagle's Eye View
Not rated yetReducing Fat & Reducing Mortality & Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes
· 9 min
In this week's View, Dr. Eagle evaluates the impacts that reducing saturated fat have on mortality, nonfatal myocardial infarction (NFMI), and stroke in high-risk individuals. He then explores the SURPASS-CVOT study which considers if tirzepatide is superior to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Next, he summarizes the FINEARTS-HF study and its investigation of finerenone and hypotension and CV outcomes according to baseline kidney function. Finally, Dr. Eagle examines how low operator volume is associated with worse transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) outcomes. Subscribe to Eagle's Eye View
Not rated yet